Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 20/20 | 0.74 |
| ▸ | DYRK1A | Q13627 | 20/20 | 0.74 |
| ▸ | WNT1 | P04628 | 14/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19515591 | 0.99 | GSK3B (0.75) | GSK3BDYRK1AWNT1 | |
| SCHEMBL30004618 | 0.99 | GSK3B (0.75) | GSK3BDYRK1AWNT1 | |
| SCHEMBL30005843 | 0.92 | GSK3B (0.75) | GSK3BDYRK1AWNT1 | |
| SCHEMBL19515662 | 0.92 | GSK3B (0.75) | GSK3BDYRK1AWNT1 | |
| SCHEMBL19515659 | 0.92 | GSK3B (0.75) | GSK3BDYRK1AWNT1 | |
| SCHEMBL19515535 | 0.85 | GSK3B (1.00) | GSK3BDYRK1AWNT1 | |
| SCHEMBL19515290 | 0.85 | GSK3B (1.00) | GSK3BDYRK1AWNT1 | |
| SCHEMBL19516459 | 0.85 | GSK3B (1.00) | GSK3BDYRK1AWNT1 | |
| SCHEMBL30005977 | 0.85 | GSK3B (1.00) | GSK3BDYRK1AWNT1 | |
| SCHEMBL30005213 | 0.85 | GSK3B (1.00) | GSK3BDYRK1AWNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673881-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | claimed |
| US-20230104155-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2023-04-06 | — | — | US | claimed |
| CN-109311819-B | Isoquinolin-3-yl carboxamides, their preparation and their use | 萨穆梅德有限公司 | 2022-10-25 | — | — | CN | claimed |
| EP-3943086-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | BioSplice Therapeutics, Inc. (US) | 2022-01-26 | — | — | EP | claimed |
| US-11174244-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2021-11-16 | — | — | US | claimed |
| EP-3448838-B1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | BIOSPLICE THERAPEUTICS INC (US) | 2021-08-11 | — | — | EP | claimed |
| US-20200339536-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2020-10-29 | — | — | US | claimed |
| US-10508099-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2019-12-17 | — | — | US | claimed |
| US-20170313681-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2017-11-02 | — | — | US | claimed |
| US-11673881-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| EP-3943086-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | BioSplice Therapeutics, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3943086-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | BioSplice Therapeutics, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| US-11174244-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| EP-3448838-B1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | BIOSPLICE THERAPEUTICS INC (US) | 2021-08-11 | — | — | EP | disclosed |
| US-10556885-B2 | Isoquinolin-3-YL carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2020-02-11 | — | — | US | disclosed |
| US-10508099-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2019-12-17 | — | — | US | disclosed |
| US-10287267-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180222887-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2018-08-09 | — | — | US | disclosed |
| US-20180208580-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2018-07-26 | — | — | US | disclosed |
| US-20170313681-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2017-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222887-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, DYRK3, DYRK1B | GSK3B 10/4885DYRK1A 1/4885WNT1 7/4885 |
| US-10556885-B2 | Isoquinolin-3-YL carboxamides and preparation and use thereof | DYRK1A, DYRK3, DYRK1B | GSK3B 10/4885DYRK1A 1/4885WNT1 7/4885 |
| US-20170313681-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, DYRK3, DYRK1B | GSK3B 10/4885DYRK1A 1/4885WNT1 7/4885 |
| US-11673881-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | DYRK1A, DYRK3, DYRK1B | GSK3B 10/4885DYRK1A 1/4885WNT1 7/4885 |
| US-20200339536-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, DYRK3, DYRK1B | GSK3B 10/4885DYRK1A 1/4885WNT1 7/4885 |
| US-10508099-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | DYRK1A, DYRK3, DYRK1B | GSK3B 10/4885DYRK1A 1/4885WNT1 7/4885 |
| US-10287267-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | DYRK1A, DYRK3, DYRK1B | GSK3B 10/4885DYRK1A 1/4885WNT1 7/4885 |
| US-20230104155-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, DYRK3, DYRK1B | GSK3B 10/4885DYRK1A 1/4885WNT1 7/4885 |
| US-11174244-B2 | Isoquinolin-3-yl carboxamides and preparation and use thereof | DYRK1A, DYRK3, DYRK1B | GSK3B 10/4885DYRK1A 1/4885WNT1 7/4885 |
| US-20180208580-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, DYRK3, DYRK1B | GSK3B 10/4885DYRK1A 1/4885WNT1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.